Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2

2019年冠状病毒病(COVID-19) 大流行 接种疫苗 病毒学 疫苗效力 免疫 免疫系统 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 医学 生物 免疫学 内科学 爆发 传染病(医学专业) 疾病
作者
Yoshiaki Oda,Yuji Kumagai,Manabu Kanai,Yasuhiro Iwama,Iori Okura,Takeshi Minamida,Yukihiro Yagi,Toru Kurosawa,Pad Chivukula,Ye Zhang,Judd L. Walson
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (4): 341-343 被引量:49
标识
DOI:10.1016/s1473-3099(24)00060-4
摘要

Of the many effective vaccines developed to combat the COVID-19 pandemic, the most notable were novel mRNA vaccines. Despite their high efficacy against the original Wuhan-Hu-1 strain and early SARS-CoV-2 variants, mRNA vaccines elicit a relatively short duration of immunity, exacerbated by immune evasion by variants leading to lower efficacy;1Menegale F Manica M Zardini A et al.Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: a systematic review and meta-analysis.JAMA Netw Open. 2023; 6e2310650Crossref PubMed Scopus (23) Google Scholar for example, mRNA vaccine effectiveness against omicron declined to below 20% within 6 months of vaccination.2Andrejko KL Pry JM Myers JF et al.Waning of 2-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection accounting for depletion-of-susceptibles bias.Am J Epidemiol. 2023; 192: 895-907Crossref PubMed Scopus (3) Google Scholar Additionally, new variants are continuing to emerge,3WHOCOVID-19 advice for the public: getting vaccinated.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/adviceDate: Dec 5, 2023Date accessed: January 2, 2024Google Scholar so the ongoing risk of COVID-19 outbreaks due to persistent viral circulation necessitates ongoing development of new vaccines to prolong vaccine-induced immunity, ideally for at least 1 year to meet new annual immunisation recommendations.3WHOCOVID-19 advice for the public: getting vaccinated.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/adviceDate: Dec 5, 2023Date accessed: January 2, 2024Google Scholar We recently reported that a booster dose of the novel mRNA vaccine, ARCT-154 (Arcturus Therapeutics Holdings, San Diego, CA, USA), a self-amplifying mRNA (saRNA) vaccine based on the SARS-CoV-2 D614G variant (B.1), induced superior immunogenicity than BNT162b2 (Comirnaty; Pfizer–BioNTech) in BNT162b2-primed adults 1 month after administration.4Oda Y Kumagai Y Kanai M et al.Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Infect Dis. 2023; (published online Dec 20.)https://doi.org/10.1016/S1473-3099(23)00650-3Summary Full Text Full Text PDF Scopus (1) Google Scholar Commenting on our Article, Herfst and de Vries5Herfst S de Vries RD Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.Lancet Infect Dis. 2023; (published online Dec 20.)https://doi.org/10.1016/S1473-3099(23)00734-XSummary Full Text Full Text PDF Scopus (0) Google Scholar noted that “whether this [improvement in RNA vaccine technology] leads to better and longer-lasting immunity warrants further investigation”. In response, we present available ARCT-154 and BNT162b2 immunogenicity data at 3-months and 6-months post-booster until data showing responses at 12 months becomes available. In our study, Japanese adults who had been primed with two doses of mRNA vaccine and a booster dose of BNT162b2 at least 3 months earlier were randomly assigned equally to receive a second booster of either ARCT-154 (n=420) or BNT162b2 (n=408).4Oda Y Kumagai Y Kanai M et al.Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Infect Dis. 2023; (published online Dec 20.)https://doi.org/10.1016/S1473-3099(23)00650-3Summary Full Text Full Text PDF Scopus (1) Google Scholar In this extension analysis, we progressively excluded any participant who displayed seropositivity on days 1, 29, 91, or 181 for SARS-CoV-2 N-protein, considered to be indicative of COVID-19 infection, leaving 332 in the ARCT-154 group and 313 participants in the BNT162b2 group eligible for inclusion at the 6-month timepoint (appendix). Both groups had similar geometric mean surrogate virus neutralising titres (GMT) at baseline (GMT ratios were 0·94 for both Wuhan-Hu-1 and Omicron BA.4/5 SARS-CoV-2 variants). 1 month post-booster, the ARCT-154 group had the previously reported superior immunogenicity against both strains (figure A); GMTs against Wuhan-Hu-1 in the ARCT-154 group was 5390 (95% CI 4899–5931, n=378) and in the BNT162b2 group was 3738 (3442–4060, n=367), with a GMT ratio of 1·44 (95% CI 1·27–1·64). 3 months post-booster GMTs were 5928 (5414–6491, n=369) in the ARCT-154 group and 2899 (2648–3175, n=356) in the BNT162b2 group, a higher GMT ratio of 2·04 (1·80–2·32). Day 91 titres were equal to or greater than day 29 titres in 205 of 369 (55·6% [95% CI 50·3–60·7]) ARCT-154 recipients, but in only 108 of 356 (30·3% [25·6–35·4]) BNT162b2 recipients. Due to different rates of antibody waning by day 181 GMTs were 4119 (95% CI 3723–4557, n=332) in the ARCT-154 group and 1861 (1667–2078, n=313) in the BNT162b2 group, maintaining a GMT ratio of 2·21 (1·91–2·57) between vaccine groups. GMTs against Wuhan-Hu-1 remained higher 180 days after ARCT-154 than GMTs observed 28 days after the BNT162b2 booster. We observed the same pattern of superior immunogenicity and slower decline in omicron BA.4/5 neutralising antibodies (figure B): GMTs increased to 2125 (95% CI 1841–2453) after ARCT-154 versus 1624 (1418–1858) after BNT162b2 at day 29, then waned to 1892 (1646–2175) after ARCT-154 and 888 (764–1031) after BNT162b2 at day 91. Between days 29 and 91 titres were stable or increased in 128 of 369 (34·7% [95% CI 29·8–39·8]) ARCT-154 recipients, compared with 36 of 356 (10·1% [7·2–13·7]) BNT162b2 recipients. The difference in neutralising activity against omicron BA.4/5 was maintained to day 181 when GMTs were 1119 (95% CI 960–1305) in the ARCT-154 group and 495 (413–595) in the BNT162b2 group, with a GMT ratio of 2·26 (1·78–2·86) in favour of ARCT-154. These data demonstrate the extended persistence of neutralising antibodies after the saRNA vaccine compared with conventional mRNA vaccine in the clinical setting, confirming the longer-lasting immunity questioned by Herfst and deVries.5Herfst S de Vries RD Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.Lancet Infect Dis. 2023; (published online Dec 20.)https://doi.org/10.1016/S1473-3099(23)00734-XSummary Full Text Full Text PDF Scopus (0) Google Scholar Because neutralising antibodies have been shown to be the main indicator of protective immunity,6Earle KA Ambrosino DM Fiore-Gartland A et al.Evidence for antibody as a protective correlate for COVID-19 vaccines.Vaccine. 2021; 39: 4423-4428Crossref PubMed Scopus (530) Google Scholar these results suggest a longer duration of protection by the saRNA vaccine. The previously demonstrated superior immunogenicity against the omicron BA.4/5 sublineage,4Oda Y Kumagai Y Kanai M et al.Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Infect Dis. 2023; (published online Dec 20.)https://doi.org/10.1016/S1473-3099(23)00650-3Summary Full Text Full Text PDF Scopus (1) Google Scholar confirmed here, suggests an improved breadth of response. Given that vaccines are being reformulated to target current predominant SARS-CoV-2 variants, notably omicron XBB.1.5 and BA.2.86 sublineages (including JN.1),7European Centre for Disease Prevention and ControlSARS-CoV-2 variants of concern as of 19 January 2024.https://www.ecdc.europa.eu/en/covid-19/variants-concernDate accessed: January 26, 2024Google Scholar further evaluation of responses to these sublineages will be best done using these new vaccines. Finally, ARCT-154 contains 5 μg of mRNA, as compared with 30 μg in BNT162b2, suggesting potential dose sparing with saRNA vaccines. We anticipate that the advantages of saRNA vaccine in new formulations could provide superior protective immunity against future emergent variants. TK is a board member and stockholder of Meiji Seika Pharma. YO, MK, YI, IO, TM, and YY are full-time employees of Meiji Seika Pharma. YK received consulting fees from Meiji Seika Pharma. PC and YZ are full-time employees with stock options in Arcturus Therapeutics. JLW received consulting fees from Arcturus Therapeutics. Download .pdf (.24 MB) Help with pdf files Supplementary appendix
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
狡猾的DNA发布了新的文献求助10
1秒前
海开心呀完成签到,获得积分10
1秒前
BAITUOBT完成签到,获得积分10
1秒前
顾矜的应助被iuuu采纳,获得10
2秒前
慕青的应助被豆子采纳,获得10
2秒前
完美世界的应助被豆子采纳,获得10
2秒前
英姑的应助被豆子采纳,获得10
2秒前
思源的应助被豆子采纳,获得10
2秒前
深情安青的应助被豆子采纳,获得10
2秒前
科研通AI65的应助被豆子采纳,获得10
2秒前
molihuakai的应助被豆子采纳,获得10
2秒前
英俊的铭的应助被豆子采纳,获得10
2秒前
情怀的应助被豆子采纳,获得10
2秒前
拈花寂完成签到 ,获得积分10
4秒前
pollen06完成签到,获得积分10
4秒前
田様的应助被FUTURE采纳,获得10
4秒前
czh发布了新的文献求助10
5秒前
molihuakai的应助被Alicezzz采纳,获得10
5秒前
犹豫雅寒发布了新的文献求助10
5秒前
YUAN关注了科研通微信公众号
5秒前
lucky的应助被taipingyang采纳,获得10
6秒前
molihuakai的应助被云隐采纳,获得10
7秒前
WHZ发布了新的文献求助10
7秒前
8秒前
ixi完成签到 ,获得积分10
8秒前
8秒前
8秒前
gsh完成签到,获得积分10
9秒前
李健的应助被酷酷的绿真采纳,获得10
11秒前
12秒前
丁丁完成签到 ,获得积分10
12秒前
可爱的函函的应助被养咩咩采纳,获得10
12秒前
13秒前
晓君发布了新的文献求助10
14秒前
XWH发布了新的文献求助10
14秒前
gsh发布了新的文献求助10
14秒前
充电宝的应助被wwwy采纳,获得50
14秒前
犹豫雅寒完成签到,获得积分20
14秒前
完美世界的应助被科研单身狗采纳,获得10
14秒前
君为臣纲的应助被aa121599采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376